Objective:Immunotherapy that blocks inhibitory pathways in T lymphocytes,such as the PD-L1/PD-1 axis,is undergoing evaluation for various solid tumors.Notably,this emerging therapeutic approach is already in clinical ...Objective:Immunotherapy that blocks inhibitory pathways in T lymphocytes,such as the PD-L1/PD-1 axis,is undergoing evaluation for various solid tumors.Notably,this emerging therapeutic approach is already in clinical trials for advanced hepatocellular carcinoma(HCC).展开更多
文摘Objective:Immunotherapy that blocks inhibitory pathways in T lymphocytes,such as the PD-L1/PD-1 axis,is undergoing evaluation for various solid tumors.Notably,this emerging therapeutic approach is already in clinical trials for advanced hepatocellular carcinoma(HCC).
